Contact Us
Close panel
Call us now !
Send us an email
Find us on the map
Home
Company
Fluorochemicals
Fluorination
Fluoromethylation
Difluoromethylation
Trifluoromethylation
S-Trifluoromethylation
O-Trifluoromethylation
Se-Trifluoromethylation
N-Trifluoromethylation
Trifluoroethylation
Tetrafluoroethylation
Pentafluoroethylation
Pentafluorosulfanylation
Perfluoroalkylation
F-Labelling Fluorination
Biofluorination
Nonfluorochemicals
API&Intermediates
Solutions
Ionic Liquids
Bridge to Biologics
MCRs Custom Solutions
Contact
Searching
Pibrentasvir
Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
ABT-530
API & Intermediates
KAPI5F03
1353900-92-1
58031952
26444308
Specification
Applications
Safety & Regulations
Product Documents
Chemical Name
Molecular Formula
Molecular Weight
Assay
Appearance
Melting Point
Packaging
Storage
Pibrentasvir
C
57
H
65
F
5
N
10
O
8
1113.2
≥99%(HPLC)
White to Off-white Solid
500mg,1g,5g and 10g
-20°C Freezer
Pibrentasvir (Synonyms: ABT-530) is a protease inhibitor potentially for the treatment of Hepatitis C Virus (HCV) infection.
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
[1]
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment
.
[2]
References:
[1] E.Gane, et al, Gastroenterology,
2016
, 151(4), pp 651-659.
[2] F.Poordad, et al, Hepatology,
2017
, 61(2), pp 389-397.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Not classified as a dangerous goods
2934990300
NONH for all modes of transport
Sales restrictions may apply.
1. Product Specification
Available on request.
2. Safety Data Sheet
Available on request.
Please inquire for pricing and availability of this product by writing email to
sales@kumidas.com
.
Back